

## **Felbamate Derived Compounds**

### Cross-Reference of Related Applications

5                    This application is a continuation of U.S. Patent Application Serial  
No. 09/913,075 filed August 8, 2001, which is a national stage filing under 35  
U.S.C. §371 of international application PCT/US00/03147 filed February 8, 2000;  
this application is also a continuation of U.S. Patent Application Serial No.  
09/925,224 filed August 9, 2001, which is a continuation of international  
10 application PCT/US00/03147 filed February 8, 2000; this application also claims  
priority from. U.S. Provisional Application 60/119,254, filed February 2, 1999, and  
U.S. Provsional Application 60/136,881, filed June 1, 1999, and U.S. Provisional  
Application 60/137,204, filed June 2, 1999; all of which are incorporated herein by  
reference.

15

### Field of the Invention

                    The present invention is directed to novel derivatives of 2-phenyl-  
1,3-propanediol dicarbamate (felbamate), and the use of such derivatives as  
therapeutic agents. More particularly, compositions comprising the present  
20 felbamate derivatives can be administered for reducing the incidence and severity of  
epileptic seizures and for preventing and treating hypoxic damage resulting from an  
ischemic event.

### Background of the Invention

25                    Felbamate (2-phenyl-1,3-propanediol dicarbamate) is a known  
pharmaceutical compound having been described in U.S. Pat. Nos. 2,884,444 and  
4,868,327, the disclosures of which are expressly incorporated herein. Felbamate is  
a modulator of NMDA (N-methyl-D-aspartate) receptor function, and a glycine site

antagonist but also has other reported mechanisms of actions.

Felbamate has also been reported to interact at the AMPA/kainate receptor, facilitate the function of the GABA receptor, and modulate Na<sup>sup.</sup>+ channel conductance. Felbamate has also been demonstrated to decrease delayed  
5 neuronal cell death after kainic acid induced status epilepticus in animals. Glycine or d-serine were able to functionally reverse the anticonvulsant and ischemic protective effect of felbamate.

Felbamate has been proposed for use in treating various neurological disorders including the control of epileptic seizures. For example, U.S. Pat. No.  
10 4,978,680 discloses the use of felbamate for the prevention and control of epileptic seizures; U.S. Pat. No. 5,082,861 relates to the use of felbamate for the prevention and control of epileptic seizures associated with complex partial seizures; and U.S. Pat. No. 5,292,772 relates to the use of felbamate for the prevention and control of epileptic seizures associated with Lennox-Gastaut syndrome. The disclosures of  
15 U.S. Pat. Nos. 4,978,680, 5,082,861 and 5,292,772 are expressly incorporated herein.

Felbamate has also been reported to have efficacy in reducing cellular damage resulting from vascular reperfusion (US Patent No. 5,462,966) and preventing and treating tissue damage resulting from an ischemic event (US Patent  
20 No. 5,055,489). For example, compositions comprising felbamate can be administered to control or prevent hypoxic damage resulting from stroke and other cerebral ischemic events. The disclosure of U.S. Pat. Nos. 5,462,966 and 5,055,489 are also expressly incorporated herein.

Felbamate was approved in July 1993 for the treatment of several  
25 forms of epilepsy. Felbamate demonstrated an excellent therapeutic index throughout preclinical and clinical trials with only relatively mild side effects observed and/or reported. In its first year of approval, between 100,000 and 125,000 patients were placed on felbamate therapy in the U.S. However, within the first year


of felbamate's wide spread use, adverse reactions were reported, notably aplastic anemia and hepatotoxicity. (See Pennell et al., *Neurology*. **45**, 456-460 (1995) and O'Neil et al., *Neurology* . **46**, 1457-1459 (1996)). The severity and frequency of occurrence of these side effects prompted a recommendation by the FDA in August  
5 1994 to withdraw patients from felbamate therapy, unless the benefit of seizure control outweighed the risk of the reported toxicities.

The present invention is directed to felbamate derivatives, and their metabolites, that exhibit therapeutic properties similar to felbamate, without the adverse reactions observed with felbamate administration. In accordance with the  
10 present invention these felbamate derivatives are used to treat neurological disorders and prevent and/or control tissue damage resulting from hypoxic conditions. More particularly, the present novel compounds are believed to be useful for treating epileptic seizures and for preventing or alleviating cellular damaged caused by myocardial or cerebral ischemic events.


The presently disclosed derivatives of felbamate have been shown to have activity as neuroprotectants and are believed to have biological activities similar to those of the parent felbamate compound. However, the present compounds have been modified to prevent the formation of metabolites that are believed to cause the adverse reactions associated with the use of felbamate.  
15 Accordingly, it is anticipated that the felbamate derivatives of the present invention can be substituted for felbamate for all the therapeutic uses that have been proposed for felbamate. In addition, many of the derivatives have enhanced activities allowing for the administration of lower therapeutically effective dosage forms.

25 Summary of the Invention

The present invention is directed to novel compounds of the general formula:



wherein X is selected from the group consisting of



and R<sub>1</sub>, R<sub>7</sub>, R<sub>8</sub>, R<sub>9</sub> and R<sub>10</sub> are independently selected from the group  
5 consisting of H, halo, alkyl, haloalkyl, -NR<sub>5</sub>R<sub>6</sub>, hydroxy, and alkoxy, R<sub>2</sub> is halo, R<sub>3</sub>  
is hydroxy or -OCONH<sub>2</sub>, R<sub>4</sub> is hydroxy or carbonyl, and R<sub>5</sub> and R<sub>6</sub> are  
independently C<sub>1</sub>-C<sub>4</sub> alkyl. These novel compounds are derivatives of felbamate;  
and in particular, the original felbamate structure has been modified to prevent the  
formation of metabolite 2-phenylpropenyl (atropaldehyde) upon administration to a  
10 warm blooded vertebrate. The formation of atropaldehyde is believed to be  
responsible for the adverse effects associated with the administration of felbamate.  
These felbamate derivatives exhibit similar activities to felbamate without the risk  
of the toxicities associated with felbamate administration. In accordance with the  
present invention compositions comprising a felbamate derivative are administered  
15 to a patient to provide neuroprotection in systemic and neurological disease and to  
treat tissue damage resulting from ischemic events. The compounds can be

administered prophylactically, acutely, subacutely, or chronically via the intravenous, oral or rectal route.

Detailed Description of the Invention

5 In describing and claiming the invention, the following terminology will be used in accordance with the definitions set forth below.

As used herein, the term "pharmaceutically acceptable carrier" encompasses any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water and emulsions such as an oil/water or water/oil emulsion, and various types of wetting agents.

10 As used herein, "effective amount" means an amount sufficient to produce a selected effect. For example, an effective amount of a neuroprotective felbamate derivative is an amount of the active agent sufficient to significantly reduce the incidence and severity of epileptic seizures. An effective amount of a hypoxia ameliorating felbamate derivative is an amount of the active agent sufficient to prevent or significantly reduce cellular damage resulting from coronary artery occlusion/reperfusion or other hypoxia inducing event.

15 The general chemical terms used in the description of the compounds of the present invention have their usual meanings. For example, the term "alkyl" by itself or as part of another substituent means a straight or branched aliphatic chain having the stated number of carbon atoms.

The term "halo" includes bromo, chloro, fluoro, and iodo.


20 The term, "parenteral" means not through the alimentary canal but by some other route such as subcutaneous, intramuscular, intraspinal, or intravenous.

25 As used herein, the term "treating" includes alleviating the symptoms associated with a specific disorder or condition and/or preventing or eliminating said symptoms.

Client Ref. 00399-04  
Atty. Dkt. 1036.003US3

The following metabolic pathway (Scheme I) of felbamate (**1**) has been proposed that leads to the reactive metabolite, 3-carbamoyl-2-phenylpropionaldehyde (**3**).

**Scheme I** The metabolism of felbamate.



3-Carbamoyl-2-phenylpropionaldehyde (3) is believed to be a reactive intermediate in the oxidation of 2-phenyl-1,3-propanediol monocarbamate (2) to the major human metabolite 3-carbamoyl-2-phenylpropionic acid (4). In addition, the aldehyde carbamate (3) was found to undergo spontaneous elimination to form the  $\alpha,\beta$  unsaturated aldehyde, 2-phenylpropenal (5), commonly known as atropaldehyde. Atropaldehyde has been proposed to play a role in the development of toxicity during felbamate therapy.


Evidence for atropaldehyde formation *in vivo* has been reported with the identification of modified N-acetyl-cysteine conjugates 7 and 8 of atropaldehyde in both human and rat urine after felbamate administration. Identification of the atropaldehyde derived mercapturic acids in urine after felbamate administration is consistent with the hypothesis that atropaldehyde is formed *in vivo* and that it reacts with thiol nucleophiles.

Based on the hypothesis that the toxicity associated with felbamate administration is directly correlated to the amount of atropaldehyde formed, the present invention is directed to the development of a new class of agents structurally related to felbamate that cannot undergo metabolism to atropaldehyde.

In accordance with the present invention the benzylic hydrogen of felbamate (1) is replaced with a substituent "R<sub>2</sub>" as shown in the following metabolic scheme (Scheme II). R<sub>2</sub> is halo, and in one preferred embodiment the substituent is a fluorine atom.








### Scheme II. Felbamate Derived Agents.




Fluorofelbamate (**12**) and fluoro monocarbamate felbamate (**13**) are derivatives of known antiepileptic agents. These agents represent a new class of anti-epileptics that, while possessing structural similarity to felbamate, will not exhibit felbamate's metabolic profile and will not induce adverse reactions such as those associated with the use of felbamate.

In accordance with one embodiment of the present invention these compounds can be further modified to include substituents at the para position of the benzene ring of the felbamate derivative to preclude the formation of other potentially toxic species via the cytochrome P450 pathway. This potential cytochrome P450 mediated toxicity may be associated with the 2-substituted-2-phenyl-1,3-propanediol-dicarbamate derivatives of the present invention by formation of electrophilic species such as **19**, which may also be formed from dihydroxy felbmate, a known metabolite of felbamate. Felbamate derivative compounds that are substituted at the para position are blocked from being metabolized by certain members of the cytochrome P450 metabolic family. For example, two preferred compounds are difluorofelbamate (**23**) and difluoro monocarbamate felbamate (**24**). These felbamate derivatives are incapable of being metabolized to atropaldehyde and also are blocked from being metabolized by certain members of the cytochrome P450 metabolic family.

Parafluoro Substituted Derivatives of Felbamate




The present invention also encompasses the derivatives of the potentially active metabolites of felbamate. In particular this includes fluoro oxazinane-dione **16** and difluoro oxazinane-dione, which are derivatives of the felbamate metabolite oxazinane-dione **9**. The structure of oxazinane-dione **9** bears  
5 intriguing similarity to several established anti-epileptic drugs including phenobarbital, phenytoin, oxazinane-dione, metharbital and ethotoin, as illustrated below:



It is anticipated, therefore, that the oxazinane-dione **9** is responsible for some  
10 aspects of felbamate's efficacy *in vivo*. As patients undergoing felbamate therapy for seizure control ingest large quantities of felbamate (grams per day), even a 1 - 2% conversion to a pharmacologically active metabolite could have significant effects. This could play an important role in the seizure control observed with felbamate, particularly if the metabolite (i.e., the oxazinane-dione) was a more  
15 potent compound. In light of the possibility that the oxazinane-dione **9** could be a metabolic precursor to the major human metabolite, acid carbamate **4**, it may be formed in significant quantities (the acid carbamate was reported to represent ~ 12%


of a dose). Because the parent oxazinane-dione **9** has been found to be unstable at relevant pH, oxazinane-diones **16** are considered candidates for development as potential antiepileptic agents. Also included in this class are cyclic congeners **21** and **22**, which may be formed from felbamate derivatives (see scheme II). Also  
5 included is **20**, which may be an unknown metabolite of felbamate **1** and could be produced from felbamate derivative **12** by the cytochrome P450 metabolism.

In accordance with one embodiment of the present invention a neurological disorder or localized ischemic event (myocardial or cerebral ischemia) is treated by administering a compound having the general structure:




10

wherein X is selected from the group consisting of




and R<sub>1</sub>, and R<sub>7</sub> are independently selected from the group consisting of H, halo, alkyl, haloalkyl, -NR<sub>5</sub>R<sub>6</sub>, hydroxy, and alkoxy, R<sub>2</sub> is Cl or F, R<sub>3</sub> is  
15 hydroxy or -OCONH<sub>2</sub>, R<sub>4</sub> is hydroxy or carbonyl, R<sub>5</sub> and R<sub>6</sub> are independently C<sub>1</sub> - C<sub>4</sub> alkyl.

In an alternative embodiment a neurological disorder or localized ischemic event (myocardial or cerebral ischemia) is treated by administering a compound having the general structure:




5 wherein X is selected from the group consisting of




and R<sub>1</sub>, and R<sub>8</sub> are independently selected from the group consisting of H, halo, alkyl, haloalkyl, -NR<sub>5</sub>R<sub>6</sub>, hydroxy, and alkoxy, R<sub>2</sub> is Cl or F, R<sub>3</sub> is hydroxy or -OCONH<sub>2</sub>, R<sub>4</sub> is hydroxy or carbonyl, R<sub>5</sub> and R<sub>6</sub> are independently C<sub>1</sub>-C<sub>4</sub> alkyl, is administered to a patient to treat a neurological disorder or myocardial or cerebral ischemia.

In accordance with one embodiment, the compound is selected from the group consisting of




and




wherein  $R_1$  is selected from the group consisting of H, halo, alkyl, haloalkyl,  $-NR_5R_6$ , hydroxy, and alkoxy,  $R_3$  is hydroxy or  $-OCONH_2$ ,  $R_4$  is hydroxy or carbonyl, and  $R_5$  and  $R_6$  are independently  $C_1$ - $C_4$  alkyl, is administered to a patient to treat a neurological disorder or myocardial or cerebral ischemia.


5 In accordance with another embodiment the compound is selected from the group consisting of



and



10 wherein  $R_1$  is selected from the group consisting of H or halo,  $R_3$  is hydroxy or  $-OCONH_2$ , and  $R_4$  is hydroxy or carbonyl, and in one preferred embodiment the compound is selected from the group consisting of




wherein R<sub>1</sub> is selected from the group consisting of H, F, Cl, CF<sub>3</sub> and hydroxy and R<sub>3</sub> is hydroxy or -OCONH<sub>2</sub>. In one preferred embodiment R<sub>1</sub> is H or F and R<sub>3</sub> is -OCONH<sub>2</sub>.

5 Compositions comprising the felbamate derivative of the present invention can be used to treat patients suffering from a neurological diseases such as epileptic seizures or can be used to prevent or treat reperfusion injuries resulting from stroke, myocardial infarction, and spinal chord perfusion-type injuries. It is believed that the felbamate derivatives of the present invention also have utility for  
10 treating conditions characterized by the presence of reactive oxygen species (ROS).


The felbamate derivative of the present invention can be combined with pharmaceutically acceptable carriers, stabilizing agents, solubilizing agents, and fillers known to those skilled in the art for administration to the patient. The compositions can be formulated using standard delivery vehicles and standard  
15 formulations for oral, parenteral or transdermal delivery.

In accordance with one embodiment a patient suffering from a neurological disorder or from a reperfusion injury can be treated with the felbamate derivatives, and/or the metabolites of the felbamate derivatives to alleviate the symptoms associated with said disorder or injury. In accordance with the present  
20 invention a method for treating patients suffering from a neurological diseases such as epileptic seizures or for treating reperfusion injuries comprises the steps of administering to the patient a composition comprising a compound is selected from the group consisting of






and



wherein  $R_1$  is selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy,  $R_3$  is hydroxy or  $-OCONH_2$ , and  $R_4$  is hydroxy or carbonyl, in combination with a pharmaceutically acceptable carrier. In one preferred embodiment the composition comprises a compound selected from the group consisting of



wherein  $R_1$  is selected from the group consisting of H, F, Cl,  $CF_3$  and hydroxy,  $R_3$  is hydroxy or  $-OCONH_2$  in combination with a pharmaceutically acceptable carrier.

When administered orally, the compounds can be administered as a liquid solution, powder, tablet, capsule or lozenge. The compounds can be used in combination with one or more conventional pharmaceutical additive or excipients used in the preparation of tablets, capsules, lozenges and other orally administrable

forms. When administered as an intravenous solution, the derivatives of the present invention can be admixed with conventional IV solutions.

The compounds of the present invention are administered at a dose range effective to alleviate the symptoms associated with the disorder. In accordance with one embodiment the felbamate derivative (active agent) is administered in a dosage form of about 0.1 mg/kg to about 5.0 g/kg, and more particularly about 0.25 mg/kg to about 1 g/kg. The dosage will vary based on the route of administration and the condition/disorder to be treated.

10 **Example 1**

**Use of an LC/MS method to quantify the two atropaldehyde derived mercapturic acids 7 and 8 in a patient population treated with felbamate.**

Although the FDA has recommended patients be given felbamate therapy only when other therapies have failed, it is estimated that 8,000-12,000 patients remain on felbamate therapy in the United States (12). While the mercapturic acids are generated from addition to glutathione, any similar nucleophile (i.e., nucleophilic amino acids of proteins or DNA bases) would be expected to undergo conjugation to atropaldehyde. The more atropaldehyde generated *in vivo* the greater the likelihood that a critical target will be alkylated, leading to toxicity. Therefore, it is reasonable to expect that the potential for toxicity will correlate to the amount of atropaldehyde formed. Further, the amount of atropaldehyde derived mercapturic acids excreted in urine will be a function of the amount of atropaldehyde formed.

In accordance with one aspect of the present invention an analytical method is described for quantifying the relevant metabolites excreted in patient urine as a measurement of a patient's susceptibility to toxicity associated with felbamate therapy. The method of determining a patient's susceptibility to adverse side effects from felbamate administration comprises the steps of obtaining a

biological sample from the patient, preferably a urine sample, quantifying the mercapturic acid metabolites present in the sample and extrapolating the amount of atropaldehyde formed. In accordance with one embodiment standard liquid chromatography and mass spectroscopy (LC/MS) is used for quantifying the relevant metabolites excreted in patient urine.

### **Materials and Methods**

**Chemicals and Instruments.** All reagents were purchased from either Aldrich Chemical Co. or Sigma Chemical Co. and were of the highest quality available. HPLC was performed on a Waters 2690 Separations Module with a Waters 484 tunable absorbance detector (at 214 nm) using a Waters Symmetry C<sub>18</sub> (2.1 mm x 150 mm) column. Mass Spectra were obtained by coupling this LC system to a Finnigan MAT LCQ ion trap mass spectrometer equipped with an electrospray ionization source. NMR spectra were recorded on a General Electric QE300 spectrometer at 300 MHz and chemical shifts are reported in ppm. Melting points were determined on a Thomas-Hoover UNI-MELT apparatus and are uncorrected.

**Synthesis. 2-Phenyl-(1,1,3,3-tetra-deuterio)-1,3-propanediol.** 2-Phenyl-(1,1,3,3-tetra-deuterio)-1,3-propanediol was obtained by reduction of diethyl phenylmalonate with LiAlD<sub>4</sub> using methodology described previously for the formation of 2-phenyl-1,3-propanediol (1). The isotopic purity of the product was determined to be ≥98% as assessed by <sup>1</sup>H NMR and GC/MS. (mp = 48 - 50 °C) <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ2.6 (s, 2H), 3.0 (s, 1H), 7.3 (m, 5H). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ49.8, 127.7, 128.5, 129.3, 139.9. GC/MS (CI-methane) MH<sup>+</sup> = 157- fragment ions: 139, 121, 106, 93. Elemental Analysis: theoretical C, 69.20; H, 7.74 found C, 68.98; H, 7.68. Molecular mass is calculated with 4 <sup>2</sup>H atoms but the instrument used for elemental analysis observes each deuterium as though it were hydrogen. Therefore,

the theoretical value for elemental analysis of hydrogen is determined based on the presence of 12 <sup>1</sup>H (i.e., 12 x 1.008 = 12.096/156.21 = 7.74%).

**2-Phenyl-(1,1,3,3-tetra-deuterio )-1,3-propanediol monocarbamate.** The d<sub>4</sub>-monocarbamate alcohol was prepared from the d<sub>4</sub>-diol using methodology described previously (1). The isotopic purity of the product was determined to be ≥98% as assessed by <sup>1</sup>H NMR and LC/MS. (mp = 71- 72°C) <sup>1</sup>H NMR ((CD<sub>3</sub>)<sub>2</sub>CO): δ3.1 (s,1H), 4.8 (bs, 2H), 7.3 (m, 5H). LC/ESI-MS: MH<sup>+</sup> = 200.0.

**3-Carbamoyl-(3,3-di-deuterio )-2-phenylpropionic acid.** The d<sub>2</sub>-acid carbamate was obtained essentially as described by Adusumalli *et al.* except that the d<sub>4</sub>-monocarbamate alcohol was used as starting material (10). The isotopic purity of the product was determined to be ≥98% as assessed by <sup>1</sup>H NMR and LC/MS. (mp = 99 - 102 °C) <sup>1</sup>H NMR ((CD<sub>3</sub>)<sub>2</sub>S<sub>0</sub>): δ 3.9 (s, 1H), 5.8 (bs, 2H), 7.3 (m, 5H), 12.4 (bs, 1H). <sup>13</sup>C NMR ((CD<sub>3</sub>)<sub>2</sub>C<sub>0</sub>): δ54.1, 127.3, 128.7, 128.7, 139.3, 155.6, 201. 7. LC/ESI-MS: MH<sup>+</sup> = 211.9. Elemental Analysis: theoretical C, 56.87; H, 5.25; N, 6.63 found C, 56.74; H, 5.31; N, 6.57.

**2-Phenyl-(1,1,3,3-tetra-deuterio )-1,3-propanediol dicarbamate.** d<sub>4</sub>-Felbamate was made using methodology described previously except that d<sub>4</sub>-monocarbamate alcohol was used as starting material (2). The isotopic purity of the product was determined to be ≥ 98% as assessed by <sup>1</sup>H NMR and LC/MS. The spectral data obtained for this compound are in agreement with published values (11). (mp = 148- 150 °C) <sup>1</sup>H NMR ((CD<sub>3</sub>)<sub>2</sub>S<sub>0</sub>): δ 3.1 (s, 1H), 6.4 (bs, 4H), 7.2 (m, 5H). LC/ESI-MS: MH<sup>+</sup> = 243.1. Elemental Analysis: theoretical C, 54.53; H, 5.83; N, 11.56 found C, 54.63; H, 5.84; N, 11.64.

**N-d<sub>3</sub>-acetyl-L-cysteine.** Acetic anhydride (d<sub>6</sub>) (0.29 g, 2.7mmol) was added to a solution of Cys(trt)-OH in 20 mL DMF and 1 mL pyridine and stirred overnight. The reaction mixture was diluted with 50 mL ether and extracted with saturated aqueous lithium bromide (2 x 50 mL). The organics were dried over sodium sulfate and the solvent was removed under reduced pressure. This

intermediate was purified by flash chromatography using 1:1 methanol and chloroform affording a white solid:  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.37-7.12 (m, 15H), 4.13 (m, 1H), 2.60 (m, 2H). The sulfide was deprotected using a solution of TFA in dichloromethane (1:1) for 2 hr. The solvents were removed under reduced pressure and the crude product was used in the next reaction.

**N- $\text{d}_3$ -acetyl-S-(2-phenylpropan-3-ol)-L-cysteine.** The  $\text{d}_3$ -Nac-alcohol was formed using methodology described previously except that N- $\text{d}_3$ -acetyl-cysteine was used in the formation of the  $\text{d}_3$ -Nac-atropaldehyde intermediate (2). The isotopic purity of the product was determined to be  $\geq 95\%$  as assessed by  $^1\text{H}$  NMR and LC/MS.  $^1\text{H}$  NMR ( $\text{D}_2\text{O}$ ):  $\delta$  2.66-3.0 (m, 6H), 3.74 (t, 1H,  $J = 5.4$  Hz), 4.4 (m, 1H), 7.3 (m, 5H). LC/MS:  $\text{MH}^+ = 301.3$ .

**N- $\text{d}_3$ -acetyl-S-(2-phenylpropanoic acid)-L-cysteine.** The  $\text{d}_3$ -Nac-acid was formed using methodology described previously except that N- $\text{d}_3$ -acetyl-cysteine was used in the reaction with 2-phenyl acrylic acid (2). The isotopic purity of the product was determined to be  $\geq 95\%$  as assessed by  $^1\text{H}$  NMR and LC/MS.  $^1\text{H}$  NMR ( $\text{D}_2\text{O}$ ):  $\delta$  2.75- 3.23 (m, 4H), 3.82 (t, 1H,  $J = 5.5$  Hz), 4.4 (m, 1H), 7.32 (m, 5H). LC/ESI-MS:  $\text{MH}^+ = 315.2$ .

**Preparation of Patient Urine Samples.** Urine samples were obtained from patient volunteers undergoing felbamate therapy for control of epileptic seizures and under the care of physicians at either the University of Virginia (Charlottesville, Virginia) or the EpiCare Center (Memphis, Tennessee). Urine samples were diluted four fold with distilled water (this was done prior to overnight shipment for samples requiring shipping) and placed in an orbital shaking water bath for  $\sim 20$  min at  $37^\circ\text{C}$  to insure that all of the analytes were in solution. 500  $\mu\text{L}$  of this diluted sample were removed and added to 100  $\mu\text{L}$  of a mixture of the four deuterated internal standards. The concentration of standards in the mixture resulted in the addition of 563 nmol  $\text{d}_4$ -felbamate, 140 nmol  $\text{d}_2$ -acid carbamate, 54.0 nmol  $\text{d}_3$ -Nac-alcohol, and 27.5 nmol  $\text{d}_3$ -Nac-acid to each 500  $\mu\text{L}$  diluted urine sample. After mixing, 200  $\mu\text{L}$  were

removed and added to 20  $\mu$ L of 20% H0Ac. This acidified sample was then applied to a preconditioned Waters "Oasis" solid phase extraction cartridge (Waters Corp., Woburn, MA). The cartridge was washed with 2 mL 0.1% HOAc followed by 3 mL 10% CH<sub>3</sub>CN/90% water (0.1 %) H0Ac. The analytes and internal standards were  
5 then eluted with 3 mL 30% CH<sub>3</sub>CN:70% (0.1 %) HOAc. This fraction was then analyzed by LC/MS without further manipulation.

**LC/MS Analysis of Urine Samples for Metabolite Quantification.**

LC/MS analysis was performed using a Waters 2690 HPLC equipped with an autosampler and a Waters 486 tunable absorbance detector. This LC system was  
10 interfaced to a Finnigan MAT LCQ ion trap mass spectrometer. A 10  $\mu$ L injection of the fraction from solid phase extraction was applied to a Waters Symmetry C<sub>8</sub> reversed phase column (33% CH<sub>3</sub>CN:67% (0.1%) H0Ac, 2.1 mm x 150 mm, 0.2 mL/min). The post-column flow was directed through a Waters 486 tunable absorbance detector (10  $\mu$ L flow cell,  $\lambda$  = 214 nm) which was used for qualitative  
15 assessment of the sample and not for quantitation. The flow was then directed to the electrospray ionization source of the LCQ.

The mass spectrometer was programmed to collect data in full scan mode from 190 - 320  $m/z$  and was tuned to maximize the signal from the analytes under the HPLC conditions. The values for the electrospray parameters were as  
20 follows: heated capillary temperature = 180°C; spray voltage = 5.6 kV; capillary voltage = 20 V; sheath gas (nitrogen) flow rate = 70; auxillary gas (helium) flow rate = 20. The automatic gain control (AGC) was on with a target ion count of  $7 \times 10^7$  ions and a maximum ion inject time of 150 ms. The scan time was  $\sim 0.5$  s. Linear response curves were observed for each analyte and internal standard pair  
25 over approximately two orders of magnitude range centered on the absolute amount of each internal standard added to the samples. The amount of analytes in the patient urine samples fell within these linear response ranges.

Quantification was achieved by integration of the peaks from the mass chromatogram for each analyte using software (Navigator 1.1) provided with the LCQ. The area (expressed as counts x seconds) of the peak for each metabolite was compared to the area for its corresponding deuterated internal standard. As the  
5 absolute amount of internal standard added per mL of urine was known, the absolute amount of analyte per mL of urine could be determined.

### **Results**

Analysis was performed on 34 urine samples from 31 patients  
10 undergoing felbamate therapy for control of epileptic seizures. As is common for epileptics, many of these patients (n = 19) were undergoing polytherapy for seizure control with the remainder (n = 12) undergoing felbamate monotherapy. The age of this patient pool (14 men and 17 women) spanned from 10-57 years old with a mean age of 37. All of the urine samples analyzed were found to contain both of the  
15 mercapturic acids, indicating that formation of atropaldehyde *in vivo* does occur in the patient population and appears to be universal. More Nac-alcohol 7 was excreted than Nac-acid 8 for all of the patients. The average ratio of Nac-alcohol to Nac-acid was 6.4, however the values varied widely (ratios = 2- 14).

The absolute amounts of the analytes excreted per mL of urine varied  
20 considerably between patients. For example, the amount of felbamate excreted ranged from  $819 \pm 8.5$  nMoles/mL (this patient had a total daily dose of 3.6 grams of felbamate) to  $10,064 \pm 515$  nMoles/mL (this patient had a total daily dose of 6.0 grams of felbamate). This illustrates the effect of urine volume on the results obtained from this method. Though the dosage difference was less than double, the  
25 difference in amount of felbamate excreted per mL was greater than ten times. Thus, to compare the results from one patient to another, the values for the metabolites were normalized to the amount of felbamate.

### Discussion

We have developed an isotope-dilution based LC/MS method to quantify the amounts of felbamate **1**, the acid carbamate **4**, and the two mercapturic acids **7** and **8** excreted in patient urine. Although the FDA has recommended  
5 patients be given felbamate therapy when other therapies have failed, it is estimated that 8,000- 12,000 patients remain on felbamate therapy in the United States (12).

Scheme I illustrates the metabolic pathway leading to atropaldehyde formation and its disposition. The aldehyde carbamate represents the “commitment” step. It is at this point that a molecule is either committed to the  
10 toxic pathway of atropaldehyde **5** or the detoxification pathway of the acid carbamate **4**. The amount of mercapturic acids **7** and **8** excreted in urine will mirror the flux through the “toxic” pathway. That is, an individual that generates high levels of atropaldehyde would be expected to have correspondingly high levels of the mercapturic acids. Therefore, the ratio of acid carbamate excreted compared to  
15 the combined mercapturic acids would describe the disposition of the aldehyde carbamate for a given patient. The values for the two mercapturic acids can be combined as they both represent the same pathway of aldehyde carbamate disposition. Of course, there are other factors that may modulate the disposition through these two pathways (i.e., co-administration of modulators of enzyme  
20 activity or glutathione levels ), but this appears to be a promising approach to evaluating the metabolic distribution between toxic and non-toxic pathways in a patient population.

We applied this LC/MS method to the analysis of 34 urine samples from 31 patients undergoing felbamate therapy for control of epileptic seizures. All  
25 of these patients have been undergoing felbamate therapy for several years, without any of the severe side effects. As the severe toxicities associated with felbamate demonstrate a mean onset time of  $\leq 6$  months, these patients probably constitute a population of “normal” or “safe” metabolizers of felbamate.



The data obtained from the urine samples is illustrated that there is a “normal” range for the distribution of the aldehyde carbamate between the acid carbamate and atropaldehyde (as represented by the mercapturic acids). There does not appear to be a significant correlation between sex or therapy type and the relative amounts of metabolites formed. An individual with high esterase activity would produce relatively more of the monocarbamate alcohol from felbamate leading to increased generation of all subsequent metabolites. However, the ratio of the metabolites may still be very similar.

By our hypothesis, alkylation of proteins by atropaldehyde may result in the generation of antigens that precipitate an immune response in a manner similar to mechanisms of immune mediated toxicity for other agents. If the toxicity due to atropaldehyde is immune mediated, then susceptibility to this toxicity will be a function not only of the formation of atropaldehyde-protein conjugates but also of a patient's immune system phenotype. Some patients may have a particular phenotype that makes them allergic to atropaldehyde-protein conjugates while others do not exhibit this response. Alternatively, everyone may have the potential for an immune response, but the amount of atropaldehyde protein conjugates produced must reach a critical level before the immune response occurs. That is, all of the patients may be producing low levels of antigens, but the levels are not normally high enough to trigger an immune response. It is not until a secondary event, such as inhibition of acid carbamate formation or glutathione depletion, occurs that the production of antigens surpasses the critical level and toxicity is manifest.

Because of the potential for an immune mediated component for felbamate toxicity by our hypothesis, it may be important to understand both an individual's level of atropaldehyde formation and their phenotype to develop a complete screening method. The method described above has demonstrated

sufficient precision for the identification of “outliers” and appears to hold potential for the monitoring of patients undergoing felbamate therapy.

## Example 2

### 5      **Synthesis of Febamate Derivatives**

#### Materials and Methods

**Chemicals and Instruments.** All reagents were purchased from Aldrich Chemical Co. and were of the highest quality available. HPLC was performed on a Waters 2690 Separations Module with a Waters 484 tunable absorbance detector (at  
10      214 nm) using a Waters Symmetry C<sub>18</sub> (2.1 mm x 150 mm) column. Mass Spectra were obtained by coupling this LC system to a Finnigan MAT LCQ ion trap mass spectrometer equipped with an electrospray ionization source. NMR spectra were recorded on a General Electric QE300 spectrometer at 300 MHz and chemical shifts are reported in ppm. Melting points were determined on a Thomas-Hoover UNI-  
15      MELT apparatus and are uncorrected.

#### Synthesis

**2-Fluoro-2-phenyl-1,3-propanediol.** 2-Fluoro-2-phenyl-1, 3-propanediol was obtained from diethyl 2-fluoro-2-phenylmalonate by lithium aluminum hydride  
20      reduction using methodology analogous to that described previously for the formation of 2-phenyl-1, 3-propanediol. (Thompson et al., *Chem. Res. Toxicol.* **9**, 1225-1229 (1996)). However, the reduction was initiated at – 40 °C and was allowed to warm to room temperature over one hour, followed by stirring for an additional 1 to 2 hours, at which time the reaction was complete by TLC. <sup>1</sup>H NMR  
25      (CDCl<sub>3</sub>): δ 7.43-7.3 (m, 5H), 4.01 (dq, 4H, *J* = 22.7, 12.3 Hz), 2.82 (bs, 2H), <sup>13</sup>C NMR (CDCl<sub>3</sub>): 138.2, 129.1, 129.1, 128.9, 125.3, 125.2, 100.4, 98.0, 67.0, 66.7.

#### **2-Fluoro-2-phenyl-1, 3-propanediol monocarbamate (13, x = Fluoro).**

The title compound was prepared from the 2-fluoro-2-phenyl-1, 3-propanediol using

methodology described previously. (Thompson et al., *Chem. Res. Toxicol.* **9**, 1225-1229 (1996)). The product thus obtained was recrystallized from ethyl ether and the purity of the product was determined to be 98% as assessed by <sup>1</sup>H NMR and LC/MS (72 % yield,  $R_{f(\text{ethyl ether})} = 0.25$ , mp = 67 – 69 °C). <sup>1</sup>H NMR ((CDCl<sub>3</sub>): δ 7.4 – 7.2 (m, 5H), 5.05 (bs, 2H), 4.52 (ddd, 2H,  $J = 20.2, 12.5, 6.5$  Hz), 3.9 (dd, 2H,  $J = 12.5, 6.5$  Hz). LC/ESI-MS:  $MH^+ = 214$ .

**3-Carbamoyl-2-fluoro-2-phenylpropionic acid (17, x = Fluoro).** 3-Carbamoyl-2-fluoro-2-phenylpropionic acid **17** was prepared from 2-fluoro-2-phenyl-1, 3-propanediol monocarbamate **13** following the procedure of Adusumalli et al, which describes the preparation of 3-carbamoyl-2-phenylpropionic acid (85 % yield,  $R_{f(\text{ethyl ether})} = 0.05$ ). <sup>1</sup>H NMR ((CDCl<sub>3</sub>): δ 9.1 (bs, 1H), 7.6-7.2 (m, 5H), 5.4 (bs, 2H), 4.8 (dd, 1H,  $J = 10, 7$  Hz), 4.72 (t, 1H,  $J = 7$  Hz).

**2-Fluoro-2-phenyl-1, 3-propanediol dicarbamate (12, x = Fluoro).** The title compound, fluoro felbamate **12**, was made from 2-fluoro-2-phenyl-1, 3-propanediol by the method of Adusumalli *et al*, which describes the preparation of felbamate *Drug. Metab. Disp.* **21**, 710-716 (1993). (82 % yield,  $R_{f(\text{ethyl ether})} = 0.20$ , mp = 69 – 72 °C). <sup>1</sup>H NMR ((CDCl<sub>3</sub>): δ 7.4-7.3 (m, 5H), 5.2 (bs, 4H), 4.48 (dq, 4H,  $J = 20.8, 14.2$  Hz). C, 56.33; H, 5.67; N, 6.57 found C, 56.24; H, 5.55; N, 6.52.

**5-Fluoro-5-phenyl-1, 3-oxazinane-2,4-dione (16, x = Fluoro).** 3-carbamoyl-2-fluoro-2-phenyl propionic acid (**17**, 0.1 mmol) and 1,1'-carbonyldiimidazole (0.25 mmol) were dissolved in dichloromethane (5 mL) and the resultant solution was magnetically stirred for 12 hours in a sealed vessel.<sup>12</sup> The mixture was purified by passage of the crude reaction mixture through a pad of silica gel (10 g) in a fritted funnel, eluting with ethyl ether, affording, after recrystallization from ethyl ether, the title compound as a white powder in 42 % yield ( $R_{f(\text{ethyl ether})} = 0.70$ , mp = 115 – 117 °C). <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.48 – 7.43 (m, 3H), 7.42 – 7.37 (m, 2H), 4.93 (dd, 2H,  $J = 24.6, 12.7$  Hz), 4.68 (t, 2H,  $J = 13$  Hz)

LC/ESI-MS:  $MH^+ = 210$ . C, 57.42; H, 3.85; N, 6.70 found C, 57.23; H, 3.88; N, 6.67.

### Example 3

#### 5     **Neuroprotection and toxicity assays**

          The fluoro derivatives synthesized were submitted to the National  
Institute of Neurological Disorders and Stroke (NINDS) for evaluation in a standard  
panel of assays. Two convulsant tests (MES and scMET), and a toxicity screen  
(rotorod in mice, positional sense and gait in rats) were employed for evaluating the  
10     compounds activity as neuroprotecting agents. These testing procedures are  
described in detail in *Molecular and Cellular Targets for Anti-epileptic Drugs*, eds.  
G. Avanzini, G. Regesta, P. Tanganelli, M. Avoli, 1997, John Libbey & Company  
Ltd, pp 191-198. The felbamate derivatives were evaluated for anticonvulsant  
activity following intraperitoneal (i.p.) administration in mice and oral  
15     administration in rats.

#### **The Maximal Electroshock Seizure (MES)**

          The MES test is a model for generalized tonic-clonic seizures and is  
used to identify compounds which prevent seizure spread. The behavioral and  
20     electrographic seizures generated in this model are consistent with the human  
disorder. In the MES test, an electrical stimulus of 0.2 s in duration (50 mA in mice  
and 150 mA in rat at 60Hz) was delivered via corneal electrodes primed with an  
electrolyte solution containing an anesthetic agent. Mice were tested at 30 minutes  
and 4 hours following doses of 30, 100 and 300 mg/kg of test compound. Rats were  
25     tested at time intervals between 0.25 and 4 hours following a standard oral dose of  
30 mg/kg. Abolition of the hindlimb tonic extensor component indicates the test  
compound's ability to inhibit MES-induced seizure spread.

### **The Subcutaneous (Metrazol) Seizure Test (scMET)**

This is a model that primarily identifies compounds that raise seizure threshold. With some minor exceptions, the pharmacological profile of the scMET seizure model is consistent with the human condition. The scMET test utilizes a  
5 dose of pentylenetetrazol (85 mg/kg in Carworth Farms No. 1 mice and 70 mg/kg in Sprague-Dawley rats) that induces clonic seizures lasting for a period of at least five seconds in 97 % (CD97) of animals tested. At the anticipated time of testing the convulsant is administered subcutaneously. The test compound is administered intraperitoneally in mice and orally in rats. Animals are observed over a 30 minute  
10 period. Absence of clonic spasms in the observed time period indicates a compound's ability to abolish the effect of pentylenetetrazol on seizure threshold. All clinically active anticonvulsants have been found to be protective in at least one of these two tests.

### **15 Minimal neurotoxicity**

Toxicity induced by a compound is detected in mice using the standardized rotorod test described by Dunham & Miya (1957). Untreated control mice, when placed on a 6 r.p.m. rotation rod, can maintain their equilibrium for a prolonged period of time. Neurological impairment can be demonstrated by- the  
20 inability of a mouse to maintain equilibrium for one minute in each of three successive trials.

Rats are examined for behavioral toxicity by the positional sense test and a gait and stance test. In the positional sense test, one hind leg is gently lowered over the edge of a table, whereupon the rat, experiencing neurological deficit, will  
25 fail to lift its leg quickly back to a normal position. In the gait and stance test, neurotoxicity is indicated by a circular or zigzag gait, ataxia, abnormal spread of the legs, abnormal posture, tremor hyperactivity, lack of exploratory behavior, somnolence, stupor or catalepsy.

## Results

The results of these evaluations (MES, scMET and toxicity (TOX)) are summarized in Tables 1-6. For the MES and scMET tests the data is presented in the form of the number of animals protected by the administered compound / total number of animals tested. For the toxicity test, data is presented in the form of the number of animals exhibiting toxic effects / total number of animals tested. Qualitative data was obtained for fluoro felbamate **12** (Tables 1 and 2A), fluoro monocarbamate felbamate **13** (Tables 1 and 2B), and flourodioxo **16** (Tables 1 and 2C) and for cyclic felbamate **21** (Tables 5 and 6B) and cyclic monocarbamate **22** (Tables 5 and 6A). More extensive quantitative data was also obtained for fluoro felbamate **12** in mice (Table 3) and rats (Table 4).

Many of the agents proposed herein are derived from felbamate **1** or it's metabolites and should possess greater metabolic stability than the corresponding parent agents. Fluoro felbamate **12** and fluoro monocarbamate felbamate **13** each show anti-seizure activity and neither appears to exhibit high levels of toxicity. Surprisingly, fluoro felbamate **12** was found to be approximately 5-10 times more active than felbamate.

Fluoro felbamate **12** showed MES protective effects at 30 mg/kg at both 30 minutes and at 4 hours (see Table 1). There are some toxic effects observed at that dosage at the 30 minute timepoint but not at 4 hours. Toxicity across time doe not occur until dosages of 300mg/kg. As shown in Table 2A, fluoro felbamate **12** provided full protection at 30 mg/kg over several timepoints. Quantitative results obtained for fluoro felbamate **12** in mice indicated a MES ED50 of approximately 20 mg/kg with a safety ratio of at least five (see Table 3). Results obtained for oral administration of fluoro felbamate **12** to rats indicated a MES ED50 of about 3 mg/kg with no toxicity at doses up to 500 mg/kg. Finally, oral administration of fluoro felbamate **12** to mice indicated a MES ED50 of about 27 mg/kg with no toxicity at doses up to 218 mg/kg.

Fluoro monocarbamate felbamate **13** showed moderate MES protection at a dosage of 100 mg/kg in mice (see Table 1). Orally protection is seen at several different timepoints at a dosage level of 30 mg/kg (see Table 2B).

5 Interestingly, fluoro oxazinane-dione **16** was found to be inactive in mice but possesses strong anti-seizure activity in rats (Tables 1 and 2C). The preliminary evaluation of Cyclic-MCF **22** and Cyclic-Felbamate **21** is summarized in Tables 5, 6A and 6B. These agents also displayed potent activity in rat models.

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190  
2191  
2192  
2193  
2194  
2195  
2196  
2197  
2198  
2199  
220

**Table 1. Qualitative Evaluation of Fluoro Derivatives in Mouse.**

<u>Mice I. P.</u>		fluoro					
Test	Dose mg/kg	fluoro		monocarbamate		fluoro dioxo	
		<u>felbamate</u>		<u>felbamate</u>			
		Time		Time		Time	
		0.5h	4.0h	0.5h	4.0h	0.5h	4.0h
MES							
	3	0/4	0/1				
	10	0/4	1/4				
	30	1/1	1/1	0/1	0/1	0/1	0/1
	100	3/3	3/3	2/3	0/3	0/3	0/3
	300	1/1	1/1	1/1	0/1	0/1	0/1
ScMET							
	30	0/1	0/1	0/1	0/1	0/1	0/1
	100	0/1	0/1	0/1	0/1	0/1	0/1
	300	0/1	0/1	1/1	0/1	0/1	0/1
TOX							
	3	0/4	0/4				
	10	0/4	0/4				
	30	1/4	0/2	0/4	0/2	0/4	0/2
	100	4/8	0/4	3/8	0/4	0/8	0/4
	300	4/4	2/2	2/4	0/2	1/4	0/2



**Table 2A. Qualitative Evaluation of Fluoro Derivatives in Rat.**

5

Rat (p.o.)		fluoro felbamate				
Dose		Time				
Test	mg/kg	0.25h	0.5h	1.0h	2.0h	4.0h
MES	30	2/4	4/4	4/4	4/4	4/4
TOX	30	0/4	0/4	0/4	0/4	1/4

10

**Table 2B. Qualitative Evaluation of Fluoro Derivatives in Rat.**

15

Rat (p.o.)		fluoro monocarbamate felbamate				
Dose		Time				
Test	mg/kg	0.25h	0.5h	1.0h	2.0h	4.0h
MES	30	0/4	3/4	0/4	1/4	0/4
TOX	30	0/4	0/4	0/4	0/4	0/4

20

**Table 2C. Qualitative Evaluation of Fluoro Derivatives in Rat.**

25

Rat (p.o.)		fluoro dioxo				
Dose		Time				
Test	mg/kg	0.25h	0.5h	1.0h	2.0h	4.0h
MES	30	0/4	1/4	1/4	1/4	2/4
TOX	30	0/4	0/4	0/4	0/4	0/4

**Table 3. Quantitative Evaluation of Fluoro Felbamate in Mouse.**

5	Test (I.P.)	ED50 (mg/kg)
	MES	19.96
	ScMET	>160.00
	TOX	115

**Table 4. Quantitative Evaluation of Fluoro Felbamate in Rat.**

15	Test (p.o.)	ED50 (mg/kg)
	MES	3.0
	ScMET	>250.00
	TOX	>500

**Table 5. Qualitative Evaluation of Fluoro Derivatives in Mouse.**

Mice I. P.		Cyclic MCF		cyclic felbamate	
Dose		Time		Time	
Test	mg/kg	0.5h	2.0h	0.5h	4.0h
MES	30	0/1	0/1	0/1	0/1
	100	0/3	2/3	0/3	0/3
	300	1/1	1/1	0/1	0/1
ScMET	30	0/1	0/1	0/1	0/1
	100	2/5	0/1	0/1	0/1
	300	2/5	0/1	0/1	0/1
TOX	30	0/4	0/2	0/4	0/2
	100	0/8	0/4	0/8	0/4
	300	0/4	0/2	0/4	0/2

**Table 6A. Qualitative Evaluation of Fluoro Derivatives in Rat.**

Rat (p.o.)		Cyclic MCF				
Dose		Time				
Test	mg/kg	0.25h	0.5h	1.0h	2.0h	4.0h
MES	30	0/4	0/4	1/4	2/4	3/4
TOX	30	0/4	0/4	0/4	0/4	0/4

**Table 6B. Qualitative Evaluation of Fluoro Derivatives in Rat.**

Rat (p.o.)		cyclic felbamate				
Dose		Time				
Test	mg/kg	0.25h	0.5h	1.0h	2.0h	4.0h
MES	30	2/4	2/4	3/4	0/4	3/4
TOX	30	0/4	0/4	0/4	0/4	0/4

## **Discussion**

The panel of proposed agents (Scheme II), several of which are structural variants of felbamate **1** and its metabolites, seeks to address the occurrence of idiosyncratic adverse reactions that have been associated with the use of felbamate **1**. The results obtained from the evaluation of five of these agents have demonstrated that these agents possess anti seizure activity and they have not, as of yet, exhibited toxicity at therapeutically relevant doses. As is normal for agents that target neurological disorders, these agents have elicited minor levels of neurotoxicity at high doses, but there appears to exist a reasonable therapeutic index. Additionally, the activity of these agents, specifically fluoro felbamate **12** and fluoro monocarbamate felbamate **13**, correlates well with the activity of the unfluorinated parent agents, felbamate **1** and monocarbamate felbamate **2**, respectively. The evaluation of Cyclic-MCF **22** and Cyclic-Felbamate **21** also demonstrated these agents to be effective in the attenuation of seizures.

## **Conclusion**

Given the success of the evaluation of fluoro felbamate **12**, fluoro monocarbamate felbamate **13**, fluoro oxazinane-dione **16**, Cyclic-MCF **22** and Cyclic-

Felbamate **21** this panel of agents represents a new class of neuro-active entities that is designed to preclude the formation of putative toxic species that may be associated with the occurrence of adverse reactions observed with the use of felbamate. Taken as a whole, this proposed panel of agents addresses the presumed relevant metabolic processes, namely metabolism to atropaldehyde and metabolism by certain members of the cytochrome P450 metabolic family.

#### **Example 4**

##### **The Hippocampal Kindling Model**

10               The hippocampal kindling model can be used to evaluate a compound's ability to affect both the expression and acquisition of focal seizures. The hippocampal kindling paradigm as described by Lothman and Williamson (Lothman, 1994) allows the temporal effects of a drug to be evaluated in a single animal. This procedure requires the surgical placement of bipolar electrodes in the ventral hippocampus of  
15               adult male Sprague-Dawley rats. Stage five behavioral seizures are produced by using a stimulus consisting of a 50 Hz, 10 s train of 1 ms biphasic 200 uA pulses delivered every 30 min for 6 hours (12 stimuli per day) on alternating days for a total of 60 stimulations (five stimulus days). Prior to evaluating a candidate's anticonvulsant activity, a drug free control period consisting of supramaximal stimulations are  
20               recorded to verify the stability of a stage five generalized seizure.

                  A single dose of the candidate compound is then administered intraperitoneally (i.p.), 15 min following the last control stimulation. The anticonvulsant activity of the drug is assessed every 30 min for three to four hours starting 15 min after administering the test material. After each stimulation, individual  
25               Racine seizure scores and after discharge durations are recorded. Rats are used again in drug trials after four to five drug- and stimulus-free days.

                  In the kindling acquisition study, drugs are tested for their ability to prevent the development of the kindled state in electrode implanted rats. The candidate

compound is administered during the kindling procedure and at a predetermined time prior to the electrical stimulus. The dosing interval and the dose of the drug are based on the compound's activity observed in the acute seizure expression studies. Results from drug-treated animals are compared to those of saline-treated rats.

5                   This treatment is repeated on stimulus days two, three, four, and five. After a stimulus-free interval of one week, the effect of prior drug treatment on kindling acquisition is assessed by challenging the animal with the kindling stimulus protocol. The standardized kindling protocol is then carried out with the behavioral seizure score and after discharge duration recorded for each rat during three 'retest days'. Saline  
10   treated rats are fully kindled at the first stimulation following the one week stimulus-free period. An active compound would be expected to lower behavioral scores and after discharge duration compared to saline control rats. The suppression or lengthening of the delay in the acquisition of the kindled response may indicate that the candidate compound can act to prevent the development of seizures. Such compounds could be  
15   termed 'antiepileptogenic'.

## Results

                  The kindled results for fluoro felbamate **12** are presented in Table 7. At a dose of 100mg/kg a significant drop in seizure score was observed along with a  
20   corresponding decrease in after discharge duration.

**Table 7. Hippocampal Kindled Rats**

Solvent: MC (M&P, SB) Route: i.p.

5	Dose: 25 mg/kg	fluoro felbamate	
	Time (min)	Seizure Score ± S.E.M.	After discharge Duration (sec) ± S.E.M
10	Control	4.71 ± 0.18	73.14 ± 4.61
	15	4.86 ± 0.14	77.29 ± 4.91
	45	4.57 ± 0.20	71.43 ± 5.50
	75	4.00 ± 0.69	64.43 ± 11.19
	105	4.57 ± 0.20	70.29 ± 4.85
	135	4.43 ± 0.57	53.86 ± 9.33
	165	4.71 ± 0.18	59.29 ± 3.28*
15	195	3.86 ± 0.67	54.00 ± 9.62
	225	4.00 ± 0.69	53.29 ± 9.03
	255	4.86 ± 0.14	64.00 ± 3.42
	Dose: 50 mg/kg		
20	Control	5.00 ± 0.00	83.71 ± 6.97
	15	3.86 ± 0.70	67.14 ± 12.39
	45	2.86 ± 0.83*	68.57 ± 20.14
	75	3.14 ± 0.83*	63.00 ± 17.45
	105	3.43 ± 0.90	60.86 ± 14.93
25	135	3.71 ± 0.64*	65.00 ± 13.10
	165	2.71 ± 0.97*	43.14 ± 14.67*
	195	3.14 ± 0.83	52.86 ± 14.59
	225	3.00 ± 0.87*	39.86 ± 10.98*
	255	2.57 ± 0.72*	33.29 ± 11.76*

**Table 7. Hippocampal Kindled Rats (continued)**

Solvent: MC (M&P, SB) Route: i.p.

5

10

15

Dose: 100 mg/kg		
Control	5.00 ± 0.00	76.00 ± 5.03
15	1.75 ± 0.73*	40.75 ± 15.74
45	1.50 ± 0.57*	29.00 ± 10.86*
75	1.88 ± 0.67*	38.63 ± 12.58*
105	2.38 ± 0.65*	53.38 ± 12.59
135	2.00 ± 0.76*	33.63 ± 12.88*
165	2.75 ± 0.65*	43.38 ± 12.79*
195	2.25 ± 0.70*	45.25 ± 13.33*
225	2.50 ± 0.73*	47.38 ± 14.80
255	2.50 ± 0.65*	45.38 ± 13.92

\* Significantly different from control.

### Dose Responses

20

Dose (mg/kg)	Number Protected / Number Tested	Seizure Score ± S.E.M.	After discharge Duration (sec) ± S.E.M.
25	0/7	4.57 ± 0.20	71.43 ± 5.50
50	3/7	2.86 ± 0.83*	68.57 ± 20.14
100	7/8 <sup>a</sup>	1.50 ± 0.57*	29.00 ± 10.86*

25

<sup>a</sup> 2/8 toxic

\* Significantly different from control.